Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 2.156 5-летний Импакт фактор: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 30, 2020 Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v15.i3.10
pages 183-196

Point Mutations in the AML1/RUNX1 Gene Associated with Myelodysplastic Syndrome

Hironori Harada
Department of Hematology/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan
Yuka Harada
International Radiation Information Center, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan

Краткое описание

Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells characterized by ineffective and inadequate hematopoiesis. Because MDS is a heterogeneous disorder, specific gene abnormalities implicated in the pathogenesis of MDS have been difficult to identify. Cytogenetic abnormalities are seen in half of the MDS patients and generally consist of partial or complete chromosome deletion or addition, whereas balanced translocations are rare. Although point mutations of critical genes had been demonstrated to contribute to the development of MDS, there was no strong correlation between these mutations and clinical features. Recently, we reported the high incidence of somatic mutations in the AML1/RUNX1 gene (which is a critical regulator of definitive hematopoiesis and the most frequent target for translocation of acute myeloid leukemia [AML]) in MDS, especially refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEBt), and AML following MDS (defined here as MDS/AML). The MDS/AML patients with AML1 mutations had a significantly worse prognosis than those without AML1 mutations. Most AML1 mutants lose trans-activation potential, which leads to a loss of AML1 function. These data indicate that AML1 point mutation is one of the major causes of MDS/AML, and "MDS/AML with AML1 mutation" represents a distinct clinicopathologic-genetic entity.


Articles with similar content:

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors
Onco Therapeutics, Vol.5, 2014, issue 3-4
Manuela Labbozzetta, Nicoletta Vivona, Paola Poma, Monica Notarbartolo, Natale D'Alessandro
Overexpression of Yin Yang 1 in the Pathogenesis of Human Hematopoietic Malignancies
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Sara Huerta-Yepez, Mario I. Vega, H. Liu, Haiming Chen, Stavroula Baritaki, James R. Berenson, Benjamin Bonavida
C/EBPα Dysregulation in AML and ALL
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 1-2
Alan Friedman, Ido Paz-Priel
Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies
Onco Therapeutics, Vol.1, 2010, issue 1-2
Sara Huerta-Yepez, Demetrios A. Spandidos, Norio Uematsu, Mario I. Vega, Loredana Militello, Ali R. Jazirehi, Stavroula Baritaki, Benjamin Bonavida
Myc Protein: Partners and Antagonists
Critical Reviews™ in Oncogenesis, Vol.5, 1994, issue 1
Juha Klefstrom, Kari Alitalo, Tomi P. Makela, Imre Vastrik, Paivi J. Koskinen